Cytoxan is named as an intervention in 4 current clinical trials in our China and USA registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is ImmunoVaccine Technologies, Inc. (IMV Inc.) (1). The most-studied condition is Relapsed Diffuse Large B-cell Lymphoma.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT04920617 · Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
|
Phase 2 | Recruiting | ImmunoVaccine Technologies, Inc. (IMV Inc.) | USA |
|
Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL
NCT07493148 · ClinicalTrials.gov ↗ · Diffuse Large B-Cell Lymphoma (DLBCL)
|
Phase 2 | Recruiting | Ou Bai, MD/PHD | China |
|
Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer
NCT05323201 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma
|
Phase 1/2 | Recruiting | The Affiliated Hospital of Xuzhou Medical University | China |
|
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH
NCT05936086 · ClinicalTrials.gov ↗ · Hemophagocytic Syndrome
|
Not applicable | Recruiting | shifeng Lou | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| ImmunoVaccine Technologies, Inc. (IMV Inc.) | 1 |
| Ou Bai, MD/PHD | 1 |
| shifeng Lou | 1 |
| The Affiliated Hospital of Xuzhou Medical University | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China and USA registers name Cytoxan as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 4 trials are recruiting: 3 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
ImmunoVaccine Technologies, Inc. (IMV Inc.) (1), Ou Bai, MD/PHD (1), shifeng Lou (1) and The Affiliated Hospital of Xuzhou Medical University (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cytoxan works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cytoxan works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cytoxan (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.